Different effects of inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction

Hypertension Research

Volumn 28, Issue 1, 2005, Pages 79-87

  Asai, Takae ^a,b   Kushiro, Toshio ^a   Fujita, Hirotaka ^a   Kanmatsuse, Katsuo ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adrenergic receptor antagonists; Angiotensin II type 1 receptor blocker; Cardiac hypertrophy; Combination therapy; Hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BRAIN NATRIURETIC PEPTIDE; DOXAZOSIN; LOSARTAN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; HEART HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART WEIGHT; HYPERTENSION; MONOTHERAPY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATENOLOL; BLOOD PRESSURE; CARDIOMEGALY; DOXAZOSIN; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; HEART RATE; HYPERTENSION; LOSARTAN; MALE; NATRIURETIC PEPTIDE, BRAIN; RATS; RATS, INBRED SHR; RNA, MESSENGER;

EID: 17844387158     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.79     Document Type: Article

References (39)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in Framingham heart study. N Engl J Med 1990; 322: 1561-1566.
2. Komuro I, Yazaki Y: Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 1993; 55: 55-57.
3. Morgan HE, Baker KM: Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991; 83: 13-25.
4. Yamazaki T, Komuro I, Zou Y, et al: Norepinephrine induced the raf-1 kinase/mitogen-activated protein kinase cascade through both α1- and β-adrenoceptors. Circulation 1997; 95: 1260-1268.
5. Goldstein DS: Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5: 86-99.
6. Beker KM, Chernin MI, Wixson SK, Aceto JF: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 1990; 259: H324-H332.
7. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86: 1913-1920.
8. Dang A, Zheng D, Wang B, et al: The role of renin-angiotensin and cardiac sympathetic nervous systems in the development of hypertension and left ventricular hypertrophy in spontaneously hypertensive rats. Hypertens Res 1999; 22: 217-221.
9. Simpson P: Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 1983; 72: 732-738.
10. Huang MH, Friend DS, Sunday ME, et al: An intrinsic adrenergic system in mammalian heart. J Clin Invest 1996; 98: 1298-1303.
11. Crabos M, Roth M, Hahn AW, Erne P: Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest 1994; 93: 2372-2378.
12. Sano H, Okamoto H, Kitabatake A, Iizuka K, Murakami T, Kawaguchi H: Increased mRNA expression of cardiac renin-angiotensin system and collagen synthesis in spontaneously hypertensive rats. Mol Cell Biochem 1998; 178: 51-58.
13. Griendling KK, Murphy TJ, Alexander RW: Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828.
14. Arita M, Horinaka S, Komatsu K, Frohlich ED: Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. J Hypertens 1993; 11 (Suppl 5): S354-S355.
15. Brilla CG: Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 2000; 46: 324-331.
16. Varagic J, Susic D, Frohlich ED: Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects. J Cardiovasc Pharmachol Ther 2001; 6: 57-63.
17. Ohta K, Kim S, Iwao H: Role of angiotensin-converting enzyme, adrenergic receptors, and blood pressure in cardiac gene expression of spontaneously hypertensive rats during development. Hypertension 1996; 28: 627-634.
18. Takeda T, Kohno M: Brain natriuretic peptide in hypertension. Hypertens Res 1995; 18: 259-266.
19. Nakagawa O, Ogawa Y, Itoh H, et al: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280-1287.
20. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K: Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25: 669-676.
21. Maeso R, Navarro-Cid J, Rodrigo E, Ruilope LM, Lahera V, Cachofeiro V: Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats. Am J Hypertens 1999; 12: 1105-1108.
22. Haneda T, Ogawa Y, Kato J, et al: Effect of celiprolol on cardiac hypertrophy in hypertension. Hypertens Res 2000; 23 467-474.
23. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57: 450-458.
24. Brown LB, Nunez DJR, Wilkins MR: Differential regulation of natriuretic peptide receptor messenger RNAs during development of cardiac hypertrophy in the rat. J Clin Invest 1993; 92: 2702-2712.
25. Terada Y, Tomita K, Nonoguchi H, Marumo F: Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. J Clin Invest 1992; 90: 659-665.
26. Ogawa Y, Nakao K, Mukoyama M, et al: Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 1991; 69: 491-500.
27. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
28. Magga J, Marttila M, Mantymaa P, Vuolteenaho O, Ruskoaho H: Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 1994; 134: 2505-2515.
29. Magga J, Kalliovalkama J, Romppanen H, et al: Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. J Hypertens 1999; 17: 1543-1552.
30. Yokota N, Aburaya M, Yamamoto Y, et al: Increased plasma brain natriuretic peptide levels in DOCA-salt hypertensive rats: relation to blood pressure and cardiac concentration. Biochem Biophys Res Commun 1990; 173: 632-638.
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2003; 42: 239-246.
32. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the losartan intervention for end-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
33. Ohta K, Kim S, Iwao H: Role of angiotensin-converting enzyme, adrenergic receptors, and blood pressure in cardiac gene expression of spontaneously hypertensive rats during development. Hypertension 1996; 28: 627-634.
34. Yamori Y, Tarazi RC, Ooshima A: Effect of beta-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats. Clin Sci (Lond) 1980; 59 (Suppl 6): 457s-460s.
35. Ohlstein EH, Vickery L, Arleth A, et al: Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 1994; 16: 163-177.
36. Lithell H, Aberg H, Selinus I: Metabolic effects of a change in antihypertensive treatment. Am J Med 1986; 80: 114-119.
37. Bezerra SM, dos Santos CM, Moreira ED, Krieger EM, Michelini LC: Chronic AT1 receptor blockade alters autonomic balance and sympathetic responses in hypertension. Hypertension 2001; 38: 569-575.
38. Pinto YM, Pinto-Sietsma SJ, Philipp T, et al: Reduction in left ventricular messenger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension 2000; 36: 747-754.
39. Linz W, Schaper J, Wiemer G, Albus U, Scholkens BA: Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol 1992; 107: 970-975.